TY - JOUR
T1 - Advances in the management of breast cancer brain metastases
AU - Sammons, Sarah
AU - Van Swearingen, Amanda E.D.
AU - Chung, Caroline
AU - Anders, Carey K.
N1 - Publisher Copyright:
© 2021 The Author(s). Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.
PY - 2021/11/1
Y1 - 2021/11/1
N2 - The development of breast cancer (BC) brain metastases (BrM) is a common complication of advanced disease, occurring in up to half of the patients with advanced disease depending on the subtype. The management of BCBrM requires complex multidisciplinary care including local therapy, surgical resection and/or radiotherapy, palliative care, and carefully selected systemic therapies. Significant progress has been made in the human epidermal growth factor receptor 2-positive (HER2+) BCBrM population due to novel brain penetrable systemic therapies. Increased inclusion of patients with BCBrM in clinical trials using brain-penetrant systemic therapies recently led to the first FDA approval of a HER2-directed therapy specifically in the BCBrM population in the last year. Advances for the treatment of HR+/HER2- and TNBC BCBrM subgroups continue to evolve. In this review, we will discuss the diagnosis and multidisciplinary care of BCBrM. We focus on recent advances in neurosurgery, radiation therapy, and systemic treatment therapies with intracranial activity. We also provide an overview of the current clinical trial landscape for patients with BCBrM.
AB - The development of breast cancer (BC) brain metastases (BrM) is a common complication of advanced disease, occurring in up to half of the patients with advanced disease depending on the subtype. The management of BCBrM requires complex multidisciplinary care including local therapy, surgical resection and/or radiotherapy, palliative care, and carefully selected systemic therapies. Significant progress has been made in the human epidermal growth factor receptor 2-positive (HER2+) BCBrM population due to novel brain penetrable systemic therapies. Increased inclusion of patients with BCBrM in clinical trials using brain-penetrant systemic therapies recently led to the first FDA approval of a HER2-directed therapy specifically in the BCBrM population in the last year. Advances for the treatment of HR+/HER2- and TNBC BCBrM subgroups continue to evolve. In this review, we will discuss the diagnosis and multidisciplinary care of BCBrM. We focus on recent advances in neurosurgery, radiation therapy, and systemic treatment therapies with intracranial activity. We also provide an overview of the current clinical trial landscape for patients with BCBrM.
KW - brain metastases
KW - breast cancer
KW - stereotactic radiosurgery
KW - surgical resection
KW - systemic therapies
UR - http://www.scopus.com/inward/record.url?scp=85126533308&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126533308&partnerID=8YFLogxK
U2 - 10.1093/noajnl/vdab119
DO - 10.1093/noajnl/vdab119
M3 - Review article
C2 - 34859234
AN - SCOPUS:85126533308
SN - 2632-2498
VL - 3
SP - V63-V74
JO - Neuro-Oncology Advances
JF - Neuro-Oncology Advances
ER -